{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:41:46Z","timestamp":1762987306950,"version":"3.45.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jtocrr.2023.100498","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T11:32:51Z","timestamp":1678534371000},"page":"100498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors"],"prefix":"10.1016","volume":"4","author":[{"given":"Thomas Yang","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon B.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasodha","family":"Natkunam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhmani","family":"Padda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"van de Rijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Riess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2023.100498_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227197","article-title":"Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States","volume":"14","author":"Hsu","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jtocrr.2023.100498_bib2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.critrevonc.2016.01.012","article-title":"Thymoma and thymic carcinomas","volume":"99","author":"Scorsetti","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtocrr.2023.100498_bib3","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2023.100498_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in\u00a0patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2023.100498_bib5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","article-title":"Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis","volume":"76","author":"Weiskopf","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2023.100498_bib6","article-title":"CD47 as a promising therapeutic target in oncology","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtocrr.2023.100498_bib7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-020-00930-1","article-title":"Role of CD47 in hematological malignancies","volume":"13","author":"Eladl","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jtocrr.2023.100498_bib8","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2023.100498_bib9","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 15","key":"10.1016\/j.jtocrr.2023.100498_bib10","article-title":"Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: phase Ib results","volume":"38","author":"Sallman","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.jtocrr.2023.100498_bib23","article-title":"374 A first-in-human phase 1\/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors","volume":"8","author":"Mahalingam","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 2","key":"10.1016\/j.jtocrr.2023.100498_bib11","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1097\/JTO.0000000000000299","article-title":"Alterations of the immune system in thymic malignancies","volume":"9","author":"Weksler","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2023.100498_bib12","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2023.100498_bib13","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1016\/j.cllc.2018.12.005","article-title":"Increased galectin-1 expression in thymic epithelial tumors","volume":"20","author":"Riess","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2023.100498_bib14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cncr.10665","article-title":"New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China","volume":"95","author":"Chen","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2023.100498_bib15","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.3390\/ijms22083836","article-title":"Transcriptomic profiles of CD47 in breast tumors predict outcome and are associated with immune activation","volume":"22","author":"Noblejas-L\u00f3pez Mdel","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtocrr.2023.100498_bib16","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1002\/cam4.2882","article-title":"Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer","volume":"9","author":"Arrieta","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtocrr.2023.100498_bib17","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00262-020-02806-2","article-title":"CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration","volume":"70","author":"Shi","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtocrr.2023.100498_bib18","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/diagnostics11040668","article-title":"Correlation of CD47 expression with adverse clinicopathologic features and an unfavorable prognosis in colorectal adenocarcinoma","volume":"11","author":"Kim","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jtocrr.2023.100498_bib19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12885-021-08045-7","article-title":"CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor","volume":"21","author":"Imam","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtocrr.2023.100498_bib20","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 WHO classification of tumors of the thymus: continuity and changes","volume":"10","author":"Marx","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2023.100498_bib21","doi-asserted-by":"crossref","first-page":"10133","DOI":"10.18632\/oncotarget.7100","article-title":"A\u00a0function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer","volume":"7","author":"Kaur","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtocrr.2023.100498_bib22","article-title":"CD47 promotes tumor invasion and metastasis in non-small cell lung cancer","volume":"6","author":"Zhao","year":"2016","journal-title":"Sci Rep"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364323000371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364323000371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:38:19Z","timestamp":1762987099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364323000371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2666364323000371"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100498","relation":{},"ISSN":["2666-3643"],"issn-type":[{"type":"print","value":"2666-3643"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100498","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100498"}}